Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes

Acta Pharmacologica Sinica

Volumn 25, Issue 8, 2004, Pages 986-990

  Hu, Yu Rong ^a   Qiao, Hai Ling ^a   Kan, Quan Cheng ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Genotype; Human CYP2C19 protein; Lansoprazole; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE;

AREA UNDER THE CURVE; ARTICLE; CHINESE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 4043107685     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. +-ATPase. Annu Rev Pharmacol Toxicol 1995; 35: 277-305.
2. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997; 17: 22-37.
3. Kita T, Sakaeda T, Baba T, Aoyama N, Kakumoto M, Kurimoto Y, et al. Different Contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull 2003; 26: 386-90.
4. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23: 460-71.
5. Jacqz E, Dulac H, Mathieu H. Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 1988; 35: 167-71.
6. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60: 661-6.
7. Shu Y, Zhou HH. Individual and ethnic differences in CYP2C19 activity in Chinese populations. Acta Pharmacol Sin 2000; 21: 193-9.
8. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-22.
9. de Morais SMF, Wilkinson GR, Blaisdell J. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-8.
10. Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14: 1259-66.
11. de Morais SMF, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, et al. Identification Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58: 404-11.
12. Goldstein JA, Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. In: Johnson EF, Waterman MR, editors. Methods in Enzymology 272, Cytochrome P450. New York: Academic Press; 1996. p 210-8.
13. Karol MD, Granneman GR, Alexander k. Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography. J Chromatogr B 1995; 668: 182-6.
14. Sohn DR, Kwon JT, Kim HK, Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4-hydroxylation phenotype status. Clin Pharmacol Ther 1997; 61: 574-82.
15. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001; 70: 484-92.